Physician profile
Tausha Rhoades
NPI 1134691512
$3,382.37
in general payments reported to CMS, 2019-2025
35 companies · $518 in 2025
The $518 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,432 · 2022: $279 · 2023: $638 · 2024: $515 · 2025: $518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,671.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $788.92 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $467.12 | 2021-2025 | |
| Pfizer INC. | $210.21 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $196.77 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $189.97 | 2021-2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $122.00 | 2021 | |
| Glaxosmithkline, LLC. | $119.19 | 2021-2023 | Trelegy Ellipta, Shingrix |
| Abbott Laboratories | $115.92 | 2021-2025 | Freestyle Libre 3 |
| Welch Allyn | $106.67 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $85.27 | 2021 | |
| Astellas Pharma US INC | $85.13 | 2021 | |
| Amgen INC. | $80.92 | 2021-2025 | Prolia, Evenity, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.04 | 2021-2023 | Jardiance |
| Esperion Therapeutics, INC. | $71.59 | 2021-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $71.57 | 2021 |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tausha Rhoades listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.